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Abstract 
 
Objective: To assess the in vitro ability of a novel lipopolysaccharide binding compound 
(EVK063) to inhibit cytokine production in lipopolysaccharide-stimulated equine 
peripheral blood mononuclear cells 
Animals: Eight healthy horses were sources for mononuclear cells. 
Procedures:  Replicate aliquots (concentrated at 4-5 million cells/mL) were stimulated 
with S. typhimurium lipopolysaccharide (LPS) (100ng/mL), treated with graded 
concentrations of EVK063, (0.01µM, 0.1µM, 1µM, 10µM), Polymyxin B (PMB) (10µM) 
and incubated at 37°C for 6 hours.  Media and cell samples were collected and stored at -
80°C for evaluation of Tumor necrosis factor (TNF) using an equine specific ELISA and 
Interleukin-6 (IL6) via qRT-PCR.  NanoDrop confirmed RNA quantity and primer sets 
designed for equine IL6 and the housekeeping gene 18s were used.  EVK063 toxicity was 
evaluated with propidium iodide staining as determined by flow cytometry.  Data was 
normalized, expressed as percent inhibition of cytokine up-regulation by LPS, and 
statistically evaluated by analysis of variance. Statistical significance was set at P ≤ 0.05. 
Results: Samples incubated in media with 0% serum demonstrated the following results: 
0.01µM and 0.1µM EVK063 maintained >90% cellular viability yet failed to 
significantly inhibit TNF production or IL6 expression.  The 1µM and 10µM EVK063 
concentrations exhibited 25% and 70% cell death respectfully and therefore an 
interpretation as to their efficacy to inhibit TNF production or IL6 expression could not 
be made.  Samples incubated in media with 10% serum demonstrated the following 
 
 
results: 0.01µM, 0.1µM and 1µM concentrations of EVK063 maintained >90% cellular 
viability yet failed to inhibit TNF production or IL6 expression.  The 10µM EVK063 
concentration exhibited 35% cell death and therefore an interpretation as to the efficacy 
to inhibit TNF production or IL6 expression could not be made.  In a whole blood 
preparation, all samples evaluated maintained >90% cellular viability.  The 10µM 
EVK063 significantly reduced TNF production and IL6 expression. 
Conclusion: This in vitro study confirms the ability of EVK063 to inhibit TNF 
production and IL6 expression in LPS stimulated equine mononuclear cells with 
comparable results to PMB. 
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Chapter 1 
Background literature 
History 
Endotoxemia is a devastating clinical condition in human and veterinary medicine.  
Despite constant medical advancements, endotoxemia remains a leading cause of death in 
the horse, and the number one non-coronary cause of death in the human intensive care 
unit accounting for greater than 215,000 deaths annually.1  The disease process 
overwhelms the hosts defense mechanisms and promotes a viscous inflammatory 
response responsible for the associated clinical signs.  One reason for the high mortality 
rate is the inability to reduce the inflammatory response due to the lack of appropriate 
non-toxic antiendotoxic therapy.   Consequently, research has focused on the cause of 
these clinical signs, their pathogenesis and potential attenuation of their effect.  As a 
result, valuable data has been generated that began over 100 years ago in Germany and 
continues even now, with investigations going on worldwide. 
Richard Pfeiffer, a German physician alongside Robert Koch, was working with the 
organism vibrio cholera when he made two important observations.2,3  Pfeiffer noticed 
the organism released two toxins, an exotoxin when alive and a heat stable toxin after 
death.2,3  He believed the heat stable toxin was sequestered by the organism while alive 
and therefore labeled it endotoxin.  Interestingly, Eugenio Centanni was making a similar 
discovery in Europe.  Centanni extracted a heat stable toxin from Salmonella typhi and 
named it pyrotoxina for its ability to induce fever.2,3  A great deal of work was done 
through the next decade analyzing these bacterial extracts.  However, it was not until the 
1920’s and 30’s that chemists determined the bacterial extracts were complex structures 
1  
 
composed of polysaccharide, phospholipid and protein.2,3  This discovery drove 
investigations into the relationship between the endotoxin structure and its associated 
clinical signs; such as hypothermic extremities, profuse sweating, weak peripheral pulses, 
and purple and congested mucous membranes.2  Further interest in septic shock was 
stimulated by the increased incidence of sepsis and death from traumatic wounds in 
human medicine associated with World War II. 
Investigations focusing on the mechanisms responsible for trauma induced shock and 
effects of bacterial infections continued in the 1950’s and 60’s.4  Animal models were 
utilized to reproduce clinical effects previously observed in human patients suffering 
from sepsis and shock.  Studies were conducted at Harvard University and the University 
of Minnesota where cardiac parameters were evaluated when anesthetized canines were 
intravenously administered endotoxin.4-6  A decrease in cardiac output, systemic blood 
pressure and venous return leading to poor tissue perfusion and death were 
demonstrated.4-6  These findings supported the association between hypotension and poor 
clinical outcome in human patients with circulatory shock. 
With research demonstrating similar clinical signs in multiple species, endotoxins 
became implicated in conditions other than traumatic wounds and septic shock.  Rooney 
et al described ‘colitis X’ in horses in 1963, where endotoxins were hypothesized to 
cause the clinical findings of fever, dehydration, diarrhea and colic.7  Carroll et al 
corroborated this hypothesis in 1965 after intraperitoneal injection of endotoxin at 
0.025mg/kg created similar clinical signs including diarrhea, hemoconcentration, severe 
leukopenia and death.8  They also demonstrated a species difference in the susceptibility 
to endotoxin.  The 0.025mg/kg used in horses was much lower than the 20mg/kg used in 
 
 
2 
mice, 0.48mg/kg in cats and 0.12mg/kg in cattle.8  The recognition of specie specific 
sensitivity led investigations to explore this phenomenon.   
Subsequent studies contributed knowledge regarding the body’s response to various 
amounts of endotoxin, including the synthesis and release of histamine, catecholamines, 
coagulation factors and arachidonic acid metabolites.9-11  Studies using anesthetized 
ponies where E. coli endotoxin was administered at different dosages (typically 150-200 
ug/kg), routes (intravenous and intraperitoneal) and concentration profiles (bolus or slow 
infusion) showed arterial hypoxemia, pulmonary hypertension, lactic acidosis, 
hypotension, leucopenia, hemoconcentration and decreased central venous pressure.12-14  
Additional in vitro and in vivo studies over the last two decades have evaluated host 
responses to systemic effects of low dose of endotoxin administration (20-30 ng/kg).  In 
addition, investigations have characterized the structure of endotoxin, cellular activation 
pathways, specific inflammatory mediators and clinical changes associated with host 
exposure to endotoxin.15-32  The information gained from these studies has proven vital 
towards the development of therapeutics, which are directly impacted by determination of 
the LPS molecule. 
Structure of Lipopolysaccharide 
Our understanding of the structure of the lipopolysaccharide molecule (LPS) and basic 
mechanisms underlying the cellular response to LPS has increased vastly in recent years 
(Fig. 1.1).  Lipopolysaccharide consists of a polysaccharide portion and a lipid called 
lipid A (Fig. 1.2).  The polysaccharide portion consists of a polymer of repeating 
oligosaccharide units, the composition of which is highly varied among Gram-negative 
bacteria.33-36  A relatively well-conserved core hetero-oligosaccharide covalently bridges 
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the polysaccharide with lipid A.33-36  The structurally highly conserved lipid A is the 
active moiety of LPS.33-36  In order for LPS to exert its toxic effect, it must be transported 
to its effector cell.  Lipopolysaccharide is hydrophobic and tends to form aggregates in 
plasma that either interact with lipopolysaccharide binding protein (LBP) or high density 
lipoproteins forming an endotoxin monomer.37-41  
Lipopolysaccharide Binding Protein   
Lipopolysaccharide binding protein (LBP) is synthesized by the liver and normally 
exists in small quantities in plasma.  As part of the acute phase response, the production 
of LBP is increased roughly 100 fold.41-43  Lipopolysaccharide binding protein binds to 
lipid A facilitating endotoxin monomer interaction with peripheral blood monocytes and 
macrophages.2,39,41,44-47  As part of its function in shuttling endotoxin to the inflammatory 
cells, LBP increases the sensitivity of the animal to endotoxin.  The LPS-LBP complex is 
transported to mononuclear phagocytes with a CD14 receptor on their surface.39,42,45,48-52   
CD14 
CD14 is a glycoprotein cell surface receptor that is attached to the cell via a 
carbohydrate linkage and whose expression is increased after LPS stimulation.39,42,45,48-52  
There are two forms of CD14; membrane bound and soluble.53  Soluble CD14 is able to 
extract LPS from the blood and stimulate cells that do not contain the membrane form of 
CD14.53  However, CD14 does not contain a transmembrane domain and therefore, the 
LPS-LBP-CD14 complex must interact with another receptor, Toll-like receptor 4 to 
exert its effect.54 
Toll-like Receptors 
 
 4 
The innate immune system recognizes bacterial products and complexes through 
pattern recognition receptors known as Toll-like receptors that bind and are activated by 
various ligands.50,55-57  Toll-like receptors are named due to their similarities with Toll, a 
plasma membrane receptor discovered in the fruit fly Drosophila melanogaster.58-60  Toll 
was determined to play an integral role in the immune function of Drosophila and later 
shown to contain a cytoplasmic domain homologous to the mammalian interleukin-1 
receptor protein.58-60  There are currently thirteen TLR’s mapped between humans and 
mice, with most mammals exhibiting between 10-15 TLR’s.  Toll-like receptor 4, a type 
1 transmembrane protein characterized by 22 leucine-rich repeats on its extracellular 
domain, was first characterized in man.61  Subsequent studies demonstrated TLR4’s 
ability to initiate an immune response.62-65  While some debate existed whether TLR2 or 
TLR4 elicited the necessary response in the LPS pathway, studies have shown that TLR4 
is required during LPS challenge.65-69  This work confirmed that TLR4 is a principle 
LPS-signal transduction molecule.  Research has also demonstrated the need for a co-
receptor to completely activate TLR4.61,70,71  This receptor is Myeloid Differentiation 
Factor 2.61,70,71   
Myeloid Differentiation Factor 2 
Myeloid Differentiation Factor 2 (MD2), a 160 amino acid secreted glycoprotein 
located on the cell surface, is required for recognition and signaling of LPS.61,70,71  The 
LPS complex is presented to MD2 where binding to the lipid A portion occurs.71,72  The 
LPS bound MD2 behaves as an activating ligand for TLR4 to form a TLR4-MD2 
heterodimer.71,72  Through these interactions, LPS is able to translocate from the cell 
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surface to the cytoplasm.  After translocation, LPS initiates a cascade of events 
eventually leading to the production of multiple cytokines. 
Nuclear Factor kappa B 
The LPS complex interacts with a universal adaptor gene (Myeloid Differentiation 
Primary Response Gene 88) that links the complex to signaling molecules with the 
purpose of activating the Nuclear Factor kappa B (NFkB) pathway.53 
Nuclear Factor kappa B is a transcription factor protein complex that is involved in 
cellular responses to stimuli, including viral and bacterial antigens such as LPS.53,62,73  
Nuclear Factor kappa B naturally exists in an inactive state as a dimer bound by Inhibitor 
kappa B (IkB) within the cytoplasm.53,62,73,74  The IkB family of proteins contain multiple 
copies of a sequence called ankyrin repeats which allow them to mask the nuclear 
localization signals (NLS) of NF-κB proteins and keep them sequestered in an inactive 
state in the cytoplasm.  Within this family, IkB-β is the most prominent isoform in the 
horse.53  In order to activate NFkB, the IkB must be phosphorylated by IkB kinase 
(IKK).53,62,73,74  Following activation, IkB kinase phosphorylates IkB leading to 
ubiquitization and eventual degradation by proteasome.53,74  After degradation of IkB, 
NFkB is released from its inactive state and translocates to the nucleus where it activates 
expression of several kB genes.53,74  These genes code for IkB, creating a positive 
feedback loop, and a variety of cytokines.53,74  These cytokines are responsible for the 
clinical signs of endotoxemia.53,74   
Cytokines 
Cytokines are small protein and glycoprotein molecules that function in both the innate 
and adaptive immune responses.  While typically host protective, during some disease 
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processes production is amplified and clinical effects can be deleterious.  Cytokines such 
as Tumor Necrosis Factor-α (TNF) and IL6 are confirmed in the pathogenesis of 
endotoxemia and the focus of many research endeavors.  Tumor Necrosis Factor and IL6 
are synthesized by mononuclear phagocytes and are responsible for many of the clinical 
signs associated with endotoxemia.  The upregulation of TNF has shown significant 
association with increased temperature, heart rate, lethargy and decreased white blood 
cell count, hypotension, hemoconcentration and endothelial dysfunction, while IL-6 
correlates with enhanced synthesis of acute phase proteins, cellular differentiation and 
increased temperature.16,17,24,26,31,32,46,75-79  Consequently, therapies aimed at reducing or 
eliminating activation of the NFkB pathway due to LPS stimulation are at the forefront of 
scientific evaluation. 
Therapeutic agents 
While there are different therapeutic approaches to endotoxemia, success comes from 
rapidly determining the underlying cause and subsequent implementation of appropriate 
therapy.  One approach is to prevent translocation of endotoxin into circulation by 
removing affected structures such as devitalized bowel or an infected umbilicus.  Another 
therapeutic approach is neutralization of the LPS molecule prior to its interaction with the 
effector cell population.  Antiendotoxin antibodies targeted against the O-antigen of the 
LPS molecule is one therapeutic option.2,3,29,80-84  These antibodies are collected from 
horses vaccinated against the core regions of the Re Salmonella mutant of the rough 
strains of J5 Escherichia coli.2,3,29,53  However, these antibodies are specific for a 
bacterial strain and therefore do not afford much crossover protection.  Additionally, 
antiendotoxin antibodies have shown conflicting results.  Studies have reported 
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improvement of clinical signs in treated adult horses while others report no improvement 
or worsening of clinical signs in foals.22,29,83,85  The exact reason for this discrepancy is 
not fully understood, however there are some explanations.  It is possible the antibodies 
were administered too late in the disease process given that the interaction between 
endotoxin and equine inflammatory cells occurs rapidly.3,22  Additionally, the 
antiendotoxin titer may be insufficient to effectively neutralize the endotoxin 
challenge.3,22  Since the toxic moiety of the LPS molecule is the inner lipid A portion, the 
O-antigen antibodies may not penetrate the molecule to bind lipid A.3,22  Therefore, the 
structurally invariant and biologically active center of LPS, lipid A, is a logical 
therapeutic target for neutralization (Fig. 1.3).   
Lipid A is composed of a hydrophilic, negatively charged bisphosphorylated 
diglucosamine backbone, and a hydrophobic domain of 6 (E. coli) or 7 (Salmonella) acyl 
chains in amide and ester linkages (Fig. 1.3).35,86-88  The anionic, amphiphilic nature of 
lipid A enables it to interact with a variety of cationic hydrophobic ligands.89  Lipid A 
receptor antagonists such as the unusual lipid A derived from Rhodobacter sphaeroides 
or Polymyxin B (PMB) are strategies that have produced mixed results.  Diphosphoryl 
lipid A from R. sphaeroides (RsDPLA) and the TLR4 antagonist E5531 inhibited binding 
of enteric LPS, cytokine release, and activity of LPS induced gene expression in human 
and murine models.90,91  However, in horses, RsDPLA and E5531 behave as potent 
agonists.90,91  This receptor-ligand interaction is suggested  to result from the composition 
of  equine TLR4.91   
Polymyxin B is a cationic amphiphilic cyclic decapeptide antibiotic isolated from 
Bacillus polymyxa that has long been recognized to bind lipid A and neutralize its toxicity 
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in vitro in animal models of endotoxemia.2,3,20,22,23,92,93  While not used in humans at 
standard antimicrobial dosages due to life-threatening toxicity, low dose PMB is a 
recognized beneficial form of therapy for endotoxemia in horses and foals.2,3,22,23,53,92  
Unlike S. typhimurium antiserum, polymyxin B exhibits beneficial effects when 
administered to endotoxemic foals by reducing TNF and IL-6 production.22  However, 
studies have shown polymyxin B to exhibit toxic side effects such as ataxia when given 
intravenously every 6 hours at high dosages such as 36000 IU/kg in horses.93  At the 
University of Georgia’s Veterinary Medical Teaching Hospital, use of polymyxin B at a 
dose of 1000-5000 IU/kg given intravenously every 12 hours for 3 days duration has not 
demonstrated toxic side effects.20  Given the potential for toxicity, it is recommended that 
polymyxin B be used judiciously in patients with renal compromise. 
Lipopolysaccharide effector cell interaction initiates a cascade that culminates in the 
production of inflammatory mediators associated with the clinical signs of endotoxemia.  
In order to reduce morbidity, antiendotoxic therapy is targeted at prevention or reduction 
of synthesis, release or action of the inflammatory mediators.2,3  Therapeutic efficacy of 
nonsteroidal anti-inflammatory drugs, specifically flunixin meglumine, results from 
prevention of prostaglandin synthesis and thromboxane while reducing clinical signs 
associated with endotoxemia.2,3,94  Another option is administration of omega-3 fatty 
acids (alpha-linolenic and eicosapentaenoic acid).3,27,95-97  The theory behind this strategy 
is to reduce the synthesis of proinflammatory cyclooxygenase-derived metabolites of 
arachidonic acid by replacing it with an alternative fatty acid.  Different studies have 
evaluated the most efficacious route for administration.  Intravenous administration of 
omega-3 fatty acid in a 20% lipid emulsion altered the fatty acid composition of 
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monocytes within 8 hours.96  These changes persisted for roughly 1 week and the 
production of thromboxane and TNF were reduced.96  Pentoxifylline is a rheologic agent 
used in humans that has demonstrated the ability to reduce production of cytokines and 
thromboxane.18,19,94,98  While the beneficial effects of pentoxifylline alone are limited19, 
when combined with flunixin meglumine the protective hemodynamic effects were 
greatly enhanced.94   
Additionally, general supportive care strategies with intravenous fluids such as 
crystalloids and colloids are commonly used.2  Currently, investigations into therapeutic 
agents that would prevent or interfere with endotoxin induced cellular activation are 
being explored.  Given that no treatment options work completely and some therapeutics 
are toxic, novel therapeutic options are constantly being explored. 
Recently, small molecule analogs of PMB have been under development.  A small-
molecule that has the binding ability of polymyxin B without the associated 
nephrotoxicity would be ideal.  It was determined that the pharmacophore necessary for 
optimal recognition and neutralization of lipid A by small molecules requires two 
protonatable positive charges so disposed that the distance between them are equivalent 
to the distance between the two anionic phosphates on lipid A (~ 14 Å; see Fig. 1.3).  
This compound would have the ability to form ionic H-bonds between the phosphates on 
the lipid A backbone and the positive charges on the compound.36 In addition, 
appropriately-positioned pendant hydrophobic functionalities are necessary to further 
enhance binding affinity and stabilize the resultant complexes via hydrophobic 
interactions with the polyacyl domain of lipid A (for a recent review, see David et al.89). 
These structural requisites were first identified in certain members of a novel class of 
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compounds, the lipopolyamines, which were originally developed, and are currently 
being used as DNA transfection (lipofection) reagents.99-102  The compounds of the 
conjugated spermine class are of particular interest because they are active in vitro and 
afford protection in animal models of Gram-negative sepsis, are synthetically easily 
accessible, and are nontoxic due to their degradation to physiological substituents 
(spermine and fatty acid).103,104   
Preliminary Data: 
Recent reports describe the synthesis and structure-activity relationships pertaining to 
the anti-endotoxic activities of several mono- and bis-acylated homologated spermine 
molecules.36  Of these, EVK063 (4e36) was found to be as active as PMB in a panel of in 
vitro assays, including inhibition of proinflammatory cytokine production in LPS-
stimulated human blood ex vivo (Fig. 1.4).  In this study, EVK063 afforded complete 
protection against LPS-induced lethality in a murine model of shock, and yet, did not 
display any signs of demonstrable toxicity.36 For the sake of brevity, only a summary of 
the in vivo data obtained in the murine model of shock is given below. The protective 
effects of 4e, the most potent compound in the human TNF inhibition assay have been 
characterized using a well-established animal model of LPS-induced lethality in mice 
sensitized by D-galactosamine.78,79  A supralethal dose (twice the dose causing 100% 
lethality) of endotoxin (200 ng/mouse) was administered intraperitoneally (i.p.) to groups 
of 5 mice sensitized with D-galactosamine.  Experimental treatments consisted of 
concurrent, separate intraperitoneal injections of graded doses of compound, and lethality 
was observed at 24 h. As is evident from Table 1.1, a clear dose-response is observed, 
with 4e affording complete (statistically significant) protection at the 100 or 
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200µg/mouse dose, and partial protection at the 50µg dose. In earlier studies on 
DOSPER, the first lipopolyamines PMB mimic that was studied,104 it was observed that 
the temporal window of protection was very short. DOSPER had to be administered 
concurrent with the LPS challenge, and significant mortality resulted when the compound 
was given even 15 minutes prior to LPS. This was attributed to the extreme hydrolytic 
susceptibility to serum esterases of the ortho-ester linkages of the oleoyl groups,104 and it 
was of interest if the amide-linked acylhomospermines would display a longer plasma 
half-life, thus affording a longer time-window of protection. It is evident from the time-
course experiment (Table 1.2) that 4e is indeed apparently much longer-lived, with near-
complete protection evident when the compound is administered 6 h prior to LPS 
challenge. In a few cohorts, the observed time window of protection was 4 h when 4e was 
administered intravenously (i.v.), and was 8h when given subcutaneously, suggesting a 
depot effect and prolonged release into systemic circulation in the latter experiments.36   
Although investigations testing the utility of EVK063 have shown promising results in 
rodent models, it has not yet been tested in a large animal model.  As mentioned earlier, 
horses are exquisitely sensitive to the effects of endotoxin and the clinical signs of 
endotoxemia have been well documented.  While not possible in rodent models, 
parametric data invaluable to enhancing our understanding of the endotoxemic cascade 
can be easily obtained in the equine, making the horse an appropriate model to study.  
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Fig. 1.1. Schematic of LPS signaling pathway 
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Fig. 1.3. Structure of Lipid A. The presence of 
anionic, hydrophilic, and hydrophobic domains 
enable the binding of cationic amphipaths to lipid A.  
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 Table 1.1. Dose-dependent protection of CF-1 mice 
challenged with a supralethal dose of 200 ng/mouse (LD100 
= 100 ng) by EVK063/4e in cohorts of five animals. 
Lethality was recorded at 24 h post-challenge. Ratios 
denote dead/total. Asterixes indicate statistically significant 
values, p<0.05. Dose (µg/mouse) Compound 4e 
200 0/5* 
100 0/5* 
50 2/5 
10 5/5 
0 5/5 Table 1.2. Time-course of protection afforded by 
EVK063/4e in the D-galactosamine sensitized CF-1 mouse 
lethality model. Animals were injected with 200 µg 4e i.p. at 
times noted with respect to LPS challenge (200 ng/mouse). 
Lethality was recorded at 24 h following LPS challenge. 
Asterixes indicate statistically significant values, p<0.05. Time of 4e 
Administration 
Lethality (dead/total) 
-6h 1/5* 
-4h 1/5* 
-2h 0/5* 
0h 0/5* 
+1h 5/5 
+2h 4/5 
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Chapter 2 
Introduction 
Despite constant medical advancements, endotoxemia remains a leading cause of death 
in the horse.1-5  Endotoxins, or lipopolysaccharides (LPS), are liberated from the outer 
leaflet of the cell wall outer membrane during either rapid proliferation or lysis of a 
Gram-negative microorganism.6  Since fermentation occurs in the hind gut of the horse, 
the gastrointestinal tract naturally contains Gram-negative bacteria and large amounts of 
LPS.7  The gastrointestinal epithelium provides a barrier to prevent LPS absorption; 
however, when epithelial disruption occurs, as in some colic (mechanical disruption) and 
colitis (inflammatory disruption) cases, clinical consequences can be devastating.  A 
similar scenario is observed in humans where gram-negative sepsis remains a leading 
cause of overall mortality and the number one non-coronary cause of death in the 
intensive care unit.8  Human hospital costs associated with the treatment of endotoxemia 
exceed 17 billion dollars annually and continue to rise.8  Considering the enormous 
economic burden and high mortality rates, an animal model with recognized sensitivity to 
LPS would be invaluable in evaluation of novel therapeutics.   
Lipopolysaccharide consists of a polysaccharide portion and a lipid called lipid A (Fig. 
1.2).  The polysaccharide portion consists of a polymer of repeating oligosaccharide 
units, the composition of which is highly varied among gram-negative bacteria.  A 
relatively well-conserved core hetero-oligosaccharide covalently bridges the 
polysaccharide with lipid A.9,10 The structurally highly conserved lipid A is the active 
moiety of LPS.11-13  
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Our understanding of basic mechanisms underlying the cellular response to LPS has 
increased in recent years.  Research contributions demonstrate LPS recognition by 
CD1414-23   via an LPS-binding acute-phase plasma protein (LBP),14,23-31 followed by 
initiation of signal transduction by Toll-like receptor-432-42 and Myeloid Differentiation 
Factor 2.32,43-47   These interactions allow translocation of LPS into the cytoplasm where 
cellular activation events lead to nuclear translocation of Nuclear Factor kappa B (NF-
κB)15,48-51 resulting in cytokine mRNA transcription.  Tumor Necrosis Factor-α (TNF) 
and Interleukin-6 (IL6) are two predominant inflammatory mediators released subsequent 
to activation of the NF-κB pathway,5,25,49-58 and are mainly secreted from the 
macrophage, the primary effector host cell associated with sepsis.20,28,58-60  Consequently, 
studies have shown both TNF and IL6 are elevated during naturally occurring, as well as 
iatrogenically-induced, endotoxemia with TNF activity slightly preceding that of 
IL6.5,53,55,56  The up-regulation of TNF expression correlates with pyrexia, tachycardia, 
lethargy and leukopenia, while IL6 correlates with up-regulation of acute phase proteins, 
cellular differentiation and pyrexia.3,5,55,61  
Therapeutic strategies attempt to bind and sequester LPS prior to its interaction with its 
effector cell.  The most recognized method involves binding Lipid A, the toxic portion of 
the LPS molecule, to mask the binding region in an attempt to decrease the inflammatory 
response.  While several options are available, none are completely effective. Anti-
endotoxin antibodies60,62-69, pentoxifylline50,62,63,70-72, polymyxin B (PMB)1,2,4,60,62,63,73,74, 
antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs)60,62,63,70,75 have minimal 
efficacy.  Additionally, each therapeutic agent does not elicit the same response in all 
species; with many having negative side effects.  
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Recently, a novel molecule, EVK063, has been developed.  EVK063 is a C16 monoacyl 
homospermine compound with comparable binding strength and potency to polymyxin 
B.76  Unlike polymyxin B, EVK063 is broken down into the metabolically non-toxic 
molecules spermine and fatty acid and therefore does not exhibit the associated oto-, 
neuro- and nephrotoxicity.76  Although investigations testing the utility of EVK063 have 
shown promising results in rodent models, it has yet to be tested in a large animal model.   
The horse is exquisitely susceptible to the effects of endotoxin and is commonly 
affected with the clinical syndrome of endotoxemia, resulting in death.  Moreover, this 
inherent sensitivity makes the horse an appropriate model for testing anti-endotoxin 
therapies.  Therefore, the purpose of this study was to assess the ability of EVK063 to 
inhibit the inflammatory response of LPS-challenged equine peripheral blood 
mononuclear cells (PBMCs) in vitro.  We hypothesize that EVK063 will inhibit cytokine 
production by endotoxin-challenged equine PBMCs in a manner comparable to PMB. 
Method Development 
Endotoxin is present throughout the environment.  Consequently, horses are naturally 
exposed to various amounts and types of endotoxin throughout their lives, creating 
biological variability.  Therefore, in order to appropriately characterize the effects of 
EVK063 on the host cell, our experimental protocol was carried out in series.  The first 
stage consisted of incubating samples in culture media without autologous serum.  This 
allowed cell-EVK063 interaction to be determined without the influence of proteins or 
other molecules.  The second stage consisted of incubating samples in culture media that 
contained 10% autologous serum.  We chose 10% serum to stay consistent with previous 
work.77,78  This permitted evaluation of potential protein interactions that have been 
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observed in previous investigations of EVK063.  The third stage consisted of incubating 
samples in whole blood to allow assessment of additional interactions not observed in the 
previous two stages. 
Materials and Methods 
First stage – with and without serum:  Whole blood was collected from eight healthy 
horses in pre-heparinized syringes using an approved institutional animal care and use 
committee protocol.  Blood was then placed into 50mL conical screw top tubes and 
allowed to settle for 30 minutes.  The plasma was layered over Ficoll® 1.077a 
(radiopaque polysucrose) in a 60/40 plasma/Ficoll ratio and centrifuged for 30 minutes at 
400 X g.  The mononuclear rich middle layer was removed, placed in a separate 50mL 
conical screw top tubes and centrifuged for 10 minutes at 400 X g.  The supernatant was 
decanted and the pellet consisting of mononuclear cells was washed with phosphate 
buffered saline.  The pellet was suspended in 1640 RPMI mediab and replicate aliquots 
(concentrated at 4-5 million cells/mL) were placed in 6 well culture plates containing 
1640 RPMI culture media without serum.  The same treatments were assigned to samples 
incubated with and without serum as designated in Table 2.1.  Samples to be stimulated 
with Salmonella typhimurium LPSc (100ng/mL)79 were treated with graded 
concentrations of EVK063, [0.01µM (E0.01), 0.1µM (E0.1), 1µM (E1), 10µM (E10)], 
and 10µM PMBd (PL), then incubated at 37°C, 5%CO2 for 6 hours.  Non LPS stimulated 
samples consisted of a control with no treatment (C), vehicle control with 10uL Dimethyl 
Sulfoxide (DMSO)e (VC), 10µM PMB control (P) and 10µM EVK063 control (EC).  
One sample was stimulated with LPS but received no treatment (L).  All wells had a final 
volume of 4mL.  Media samples were collected and stored at -80°C for TNF protein 
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analysis while RNA was harvested using a commercial kit (Qiagen, Valencia, CA) and 
stored at -80°C for IL6 gene expression analysis.  Following analysis, samples were 
incubated in culture media that contained 10% autologous serum.  Treatments were 
assigned to samples as designated in Table 2.1.  Following analysis of the intial 
experiment, the study was replicated with samples incubated with 10% autologous serum, 
a whole blood model was developed.  
Second stage – whole blood: Whole blood was collected from each horse via jugular 
veinapuncture into a syringe containing 50µL heparin per 1mL blood.  Nine milliliters of 
heparanized blood was placed into each of 6 T-75 culture flask’s containing 9mL of 1640 
RPMI media.  Treatments were assigned as designated in Table 2.2.   
Non LPS stimulated samples consisted of a control with no treatment (C), 10µM PMB 
control (P) and 10µM EVK063 control (EC).  Three samples were stimulated with 
2ng/mL Salmonella typhimurium LPS.  One sample received no treatment (L), one 
received 10µM PMB (PL) and one received 10µM EVK063 (EL).  Flask’s were placed 
on an agitator and incubated at 37ºC, 5% CO2 for 6 hours.  After incubation, the diluted 
whole blood was removed and layered over 20 mL of Ficoll 1.077 in a 50 mL conical 
screw top tube and centrifuged for 30 minutes at 400 X g.  The mononuclear rich middle 
layer was removed and placed in a separate 15mL conical screw top tube and centrifuged 
for 10 minutes at 400 X g.   The supernatant was decanted and frozen at -80ºC for TNF 
evaluation.  The cell pellet was washed with Phosphate Buffered Saline (PBS) and 
subsequently disrupted to allow collection of 200µL for flow cytometry.  The remaining 
cell suspension was centrifuged for 10 minutes at 400 X g to create a cell pellet.  
Ribonucleic acid (RNA) was harvested using a commercial kit (Qiagen, Valencia, CA).   
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RNA Isolation 
The cell pellet was disrupted using Buffer RLT Plus.  The solution was then transferred 
to a QIAshredder spin column and centrifuged for 2 minutes at 16.1g.  The homogenized 
lysate was transferred to a gDNA Eliminator spin column to which an equal volume of 
70% ETOH was added and centrifuged at 16.1g for 30sec.  The samples were washed 
once with RW1 Buffer and twice with RPE Buffer and centrifuged following 
instructions.  RNase-free water was added to the spin column and centrifuged at 16.1g for 
1min, allowing collection of the RNA into an RNase-free collection tube.  Storage 
solution (RNA) was added in equal volume to each sample.  The samples were aliquoted 
in 10µL increments and frozen at -80ºC.  NanoDrop confirmed RNA quantity and IL6 
gene expression was analyzed using qRT-PCR (Invitrogen, Carlsbad, CA) with primer 
sets specific for equine IL6 and 18s (Table 2.3).   
Real Time quantitative Reverse Transcription Polymerase Chain Reaction (qRT-
PCR) 
The SuperScript III Platinum One-Step Quantitative RT-PCR system (Invitrogen, 
Carlsbad, CA) in combination with sequence specific primers and a labeled fluorogenic 
probe was employed for the analysis of IL6 message.  Analysis of the housekeeping gene 
18s was performed in the presence of 0.2x SYBR green I (Molecular Probes, Eugene, 
OR) with primers obtained from a commercially available equine kit (TaqMan, ribosomal 
RNA, Applied Biosystems, Foster City, CA).  All qRT-PCR reactions were run on a 
Cepheid SmartCycler (Sunnyvale, CA) with RNA from treated cells.  Thermocycling 
protocols for IL6 were as follows: Stage 1; 50.0°C for 120 seconds, 95.0°C for 600 
seconds; Stage 2; 40 cycles of 95.0°C for 15 seconds, 63.0°C for 30 seconds, 72.0°C for 
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30 seconds, 78.0°C for 7 seconds, 78.0°C for 13 seconds.  Melt Curves were performed 
at 60.0°C to 95.0°C at 0.2°C/second.  Gel electrophoresis in the presence of 2% ethidium 
bromide confirmed that IL6 was produced at 214 base pairs.   
Tumor Necrosis Factor Quantification 
Quantification of TNF was by an equine specific ELISA kit (Endogen®, Rockford, IL).  
The technique will be described with incubation occurring at room temperature unless 
otherwise stated.  Briefly, 100µL of coating antibody in carbonate/bicarbonate buffer 
solution was placed in each well and incubated overnight at 4ºC.  Blocking buffer was 
then added to each well for 1 hour.  After a 3 wash cycle with PBS’T, the appropriate 
dilution of standard and samples were then added to each well and incubated for 90 
minutes.  The wells were then washed 3 times with PBS’T and 100µL of detection 
antibody solution added to each well.  Following 60-minute incubation and a wash cycle, 
100µL of streptavidin-HRP was added and the wells incubated for 30 minutes.  Another 
wash cycle was performed and 100µL of substrate placed in each well.  The plate was 
incubated in the dark for 20 minutes.  A stop solution of H2SO4 was added prior to 
reading on a micro-elisa plate reader. 
Flow Cytometry 
Cellular viability was determined using propidium iodide staining (PI, 2 mg ml-1) a dye 
that intercalates with nucleic acids to determine if an interruption in the cell membrane 
existed following damage or cell death.  Duplicate 200µL aliquots from each sample 
were reserved for analysis of cellular viability.  One aliquot served as control and the 
second aliquot received 10µL of Propidium Iodide.  Samples were run on the FACS 
Calibur (Becton Dickinson Immunocytometry system serial # E4400). 
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Synthesis of EVK063: The compound was synthesized using published procedures76 as 
summarized in Scheme 1. 
N
N
H2N
H2N
H
H
N
N
BocHN
N
Boc
Boc
H2N
Boc
NH2N
H
NHNHN
H
O
Me
. 4CF3COOH
NHN
Boc
NBocNHN
Boc
R
O
Scheme 1. Reagents: (a) RCOOH, EDCI, THF, 10 h
1 2
3e, R = C16H33 4e, n = 15;
n
a
TFA
62-86%
56-82%
3 Steps
(41% overall)
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Statistics 
Statistical evaluation was performed using Analysis of Variance with significance set at 
p≤0.05.  Using the mean squares for treatment and error, the F statistic allowed 
acceptance or rejection of the research hypothesis.  Multiple pairwise comparisons of 
treatment means were made using the Tukey method.  The experimental error rate was 
set at 0.05.  All computations were performed using Statistical Analysis Software (SAS® 
Cary, NC).  The data was then normalized to the control sample (100% inhibition) and 
the LPS sample (0% inhibition) for presentation. 
Results 
Samples incubated without serum 
Lipopolysaccharide stimulated equine PBMC’s were incubated without serum and 
evaluated for TNF production and IL6 expression.  All samples were treated under the 
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same conditions to minimize variability in technique.  Tumor necrosis factor ELISA 
analysis revealed a concentration dependent reduction in TNF production (Fig 2.1, Table 
2.4).  Non LPS stimulated samples (C, VC, P, EC) demonstrated significantly lower TNF 
production when compared to the non-treated LPS stimulated sample (L), but did not 
show significance between each other.  Samples stimulated with LPS and treated with 
0.01µM, 0.1µM and 1µM concentrations of EVK063 were unable to reduce TNF 
production by more that 27% when compared to the untreated LPS stimulated sample.  
The 10µM EVK063 concentration inhibited TNF production (84-98%), which was 
consistent with the LPS stimulated 10µM PMB treated sample.   
Interleukin-6 analysis by qRT-PCR was performed in the same manner as described for 
TNF analysis.  Samples were normalized to control and fold increase in IL6 gene 
expression was determined (Fig 2.2, Table 2.4).  Non LPS stimulated samples (C, VC, P, 
EC) showed statistical significance in IL6 expression when compared to the untreated 
LPS stimulated sample, but did not show significance between each other.  At 0.01µM, 
0.1µM, and 1µM concentrations there was no effect of EVK063 on IL6 expression in 
LPS treated cells.  The 10µM EVK063 significantly reduced IL6 expression (67-82%), 
similar to the effect of 10µM PMB treatment.   
Flow Cytometry of samples incubated without serum  
Cellular viability between 94-97% was maintained in the following samples: C, VC, L, 
E0.01, E0.1, P and PL.  However, the E1 sample exhibited 15-25% cell death while the 
EC and E10 samples exhibited 62-72% cell death. 
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Samples incubated with 10% Autologous serum 
Equine PBMCs were evaluated in culture media that contained 10% autologous serum 
using the same 10 treatment conditions as previously developed (Fig. 2.3, Table2.5).  
Non LPS stimulated samples (C, VC, P, EC) demonstrated significantly lower TNF 
production when compared to the untreated LPS stimulated sample, but did not show 
significance between each other.  Inhibition of TNF at 0.01µM, 0.1µM and 1µM 
EVK063 concentrations ranged from 5-37%.  The 10µM EVK063 sample inhibited TNF 
production (86-97%), which was comparable to the LPS stimulated 10µM PMB treated 
sample.  
 Interleukin-6 analysis by qRT-PCR was performed with 10% autologous serum as 
described for TNF analysis.  Samples were normalized to control and fold increase in IL6 
gene expression was determined (Fig. 2.4, Table 2.5).  Non LPS stimulated samples (C, 
VC, P, EC) demonstrated statistical significance in IL6 expression when compared to the 
untreated LPS stimulated sample but did not show significance between each other.  The 
0.01µM, 0.1µM, and 1µM EVK063 concentrations showed minimal reduction in IL6 
expression when compared to the untreated LPS stimulated sample.  Interleukin-6 
expression was reduced (71-84%) in the LPS stimulated 10µM EVK063 sample, which 
was comparable to the LPS stimulated 10µM PMB treated sample.   
Flow Cytometry of samples incubated with 10% Autologous serum 
Cellular viability between 92-97% was maintained in the following samples: C, VC, L, 
E0.01, E0.1, E1, P and PL.  EC and E10 samples exhibited 35-39% cell death. 
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Samples incubated with whole blood 
The following samples were used in the whole blood model: C, L, P, PL, EC, E10.  The 
10µM EVK063 concentration inhibited tumor necrosis factor production (73-81%) (Fig 
2.5) and IL-6 gene expression (69-75%) (Fig 2.6) at levels similar to the 10µM PMB 
sample.  
Flow Cytometry of Samples incubated with whole blood 
All samples maintained 92-98% cellular viability.   
Discussion 
Data from this investigation demonstrates the ability of EVK063 to reduce TNF 
production and IL6 expression by LPS stimulated mononuclear cells in vitro with 
comparable results to PMB.  EVK063 is a novel lipopolysaccharide binding 
pharmacophore with the ability to attenuate the effects of endotoxemia in lab animal 
models with comparable results to PMB.  We chose to evaluate TNF and IL6 due to their 
documented role in endotoxemia and to remain consistent with previous work regarding 
evaluation of PMB.1,2,4,52,73   
We examined EVK063 at concentrations of 0.01µM, 0.1µM, 1µM and 10µM.  A 10µM 
PMB concentration served as the standard for inhibition of cytokine synthesis.  Previous 
investigations have demonstrated the ability of EVK063 to bind LPS in a similar manner 
to PMB. 80  Therefore, we chose 10µM PMB to stay consistent with previous work and to 
obtain the same concentration as the highest sample of EVK063.80   
Originally all 8 samples were incubated in culture media without autologous serum.  
This allowed evaluation of the EVK063-cell interaction without interference from protein 
or other plasma constituents.  While the 10µM sample demonstrated inhibition of TNF 
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production and IL6 expression comparable to PMB, the lower concentrations of EVK063 
did not exhibit greater than 30% inhibition.  However, flow cytometry determined the 
samples containing 10µM EVK063 experienced 70% cell death and the 1µM EVK063 
sample experienced 25% cell death.  All other treatments groups experienced less than 
7% cell death.  We were concerned the higher concentrations of EVK063 created an 
unsuitable osmolar environment that may have lead to cell lysis, however, media from all 
samples were evaluated with an osmometer and determined to be within normal range 
(300-330mOsm).  Given the amount of cell death, confirmation as to the efficacy of 
EVK063 at 1µM and 10µM concentrations could not be made.   However, we concluded 
that the treatment groups containing 0.01µM and 0.1µM EVK063 were ineffective at 
inhibiting TNF production and IL6 expression under 0% serum conditions. 
We then evaluated all sample conditions in culture media with 10% autologous serum 
to determine if the toxicity at 1µM and 10µM concentrations of EVK063 could be 
attenuated, or the efficacy of the 0.01µM and 0.1µM concentrations of EVK063 
enhanced. 
Tumor necrosis factor and IL6 inhibition results with 10% autologous serum conditions 
were similar to our first trials without serum.  We were able to determine that the 
0.01µM, 0.1µM and 1µM EVK063 concentrations were ineffective at inhibiting TNF 
production and IL6 expression in LPS stimulated mononuclear cells under 10% serum 
conditions. However, cell death was reduced from 70% to 35%, for without and with 
serum respectively, in the 10µM EVK063 samples and 8% in the 1uM concentration as 
confirmed by flow cytometry.  Even though cell death was reduced to 35% for 10µM 
concentrations, we considered this value unacceptable and an interpretation could not be 
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made about the efficacy of the 10µM EVK06 concentration.  Following these results we 
evaluated the 10µM concentration of EVK063 in a whole blood model. 
We used previous whole blood and ex vivo models evaluating PMB to determine the 
amount of LPS used for stimulation.1,3,4,61,79  Evaluation of whole blood samples again 
showed a reduction in TNF production and IL6 expression when compared to non-treated 
LPS stimulated samples.  Evaluation of samples via flow cytometry demonstrated no 
difference in cell death between control and treated samples.  Therefore, the results from 
the whole blood model confirmed the ability of EVK063 at a 10µM concentration to 
attenuate cytokine production from LPS stimulated mononuclear cells with comparable 
results to 10µM PMB.  
The improvement in cell viability after adding autologous serum to the culture media 
was not unexpected.  Previous work in murine models demonstrated attenuation of 
toxicity when the compound was administered in conjunction with albumin.76  These 
findings indicate a fraction of the compound binds to albumin and thus reduces toxicity.76  
The mechanism of this attenuation is unclear at this time.76  However many endotoxic 
patients are hypoproteinemic, therefore, further investigations should evaluate the amount 
of protein binding by EVK063.   
A shortcoming of this study is the low number of samples in the whole blood model.  
While we concluded the ability of a 10µM concentration of EVK063 to inhibit TNF 
production and IL6 expression, additional samples are required to increase the power and 
validity of these findings.  Additionally, we only evaluated a 10µM concentration of 
EVK063 in the whole blood model.  Therefore, while we concluded that the 0.01µM, 
0.1µM and 1µM EVK063 concentrations were ineffective at inhibiting TNF production 
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and IL6 expression under 0% and 10% serum conditions; these concentrations should be 
evaluated in a whole blood model.   
Additional whole blood investigations should also evaluate the potential for synergistic 
effects with known therapeutic options, such as Polymyxin B.  Polymyxin B is a cationic, 
amphiphilic cyclic decapeptide antibiotic that has long been recognized to bind lipid A 
and neutralize its toxicity in animal models of endotoxemia both in vitro and in 
vivo.1,2,4,62,63,73,74,81  However, side effects of Polymyxin B including neurotoxicity and 
nephrotoxicity are well documented.  Therefore, Polymyxin B is a recognized beneficial 
form of therapy in endotoxemic horses and foals, but must be used judiciously.2,4,60,62,63,73  
In order to reduce the toxic effects of PMB, investigations have evaluated conjugating 
PMB with additional molecules such as dextran-70.2,82,83  Dextran-70 was chosen due to 
its use as a plasma expander and its molecular weight limits the loss of PMB from the 
intravascular space.82  The conjugated molecule of Polymyxin B-Dextran-70 (PMB-70) 
has demonstrated the ability to neutralize endotoxin in a murine, equine and ovine model 
of endotoxemia.2,82,83  Additionally, neither neurotoxocity or nephrotoxicity were 
observed in the equine model.2  However, specie specificity often precludes the use of 
novel therapeutics.      
Species specificity has made the development of novel antiendotoxic therapeutics 
challenging.  Antiendotoxic therapeutics such as Rhodobacter sphaeroides and E5531 
have shown promising results in lab animal models yet have failed to demonstrated 
beneficial effects in the equine model.84,85  In some cases they acted as an agonist after 
LPS stimulation in equine mononuclear cells.84,85  One explanation for these differences 
is structural modification of the molecule within the equine model.84  While there are no 
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data to support the theory, it was suggested by the authors that neutrophils may release 
enzymes that could alter the biological activity of the compound.84   
Even with constant advancements in therapeutics, endotoxemia remains a devastating 
clinical problem for both human and veterinary practitioners.   
While fewer than 100 cases were documented prior to 1920, sepsis is now recognized 
to be one of the leading causes of mortality and the number one non-coronary cause of 
death in the human intensive care unit, accounting for greater than 215,000 deaths a 
year.86  While known therapeutics like PMB are recognized as short term treatment 
options for animal models, the life threatening toxicity in humans precludes its use.  
Therefore, a molecule with the ability to bind LPS with the same potency as PMB 
without exhibiting the toxic side effects would be ideal.  This investigation demonstrates 
the ability of EVK063, a novel lipopolysaccharide binding pharmacophore, to inhibit 
cytokine synthesis from LPS stimulated equine mononuclear cells in vitro. 
   While much work is still required prior to ex vivo and in vivo assessment of EVK063, 
a positive groundwork has been established.  This in vitro study confirms the ability of 
EVK063 to inhibit TNF production and IL6 expression in LPS stimulated equine 
mononuclear cells with comparable results to PMB. 
 
aFicoll® 1.077; Sigma-Aldrich®; St. Louis, MO 
bHyQ® RPMI-1640 Medium (1x); Logan, UT 
cLipopolysaccharide from S. typhimurium; List Biological Laboratories; Campbell, CA 
dPolymyxin B; Bedford LaboratoriesTM; Bedford, OH 
eDimethyl Sulfoxide; Sigma-Aldrich®; St. Louis, MO 
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 Sample ID  
C Control 
VC Vehicle Control (10 µL DMSO) 
L LPS 
P PMB (10 µM) 
PL PMB (10 µM) + LPS 
EC EVK063 10 µM 
E10 EVK063 10 µM + LPS 
E1 EVK063 1 µM + LPS 
E0.1 EVK063 0.1 µM + LPS 
E0.01 EVK063 0.01 µM + LPS 
Figure Legend 
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Figure 2.1: Tumor Necrosis Factor inhibition: cells incubated 
without serum 
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Figure 2.2: Interleukin-6 inhibition: cells incubated without 
serum 
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Figure 2.3: Tumor Necrosis Factor inhibition: cells 
incubated with 10% autologous serum 
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Figure 2.4: Interleukin-6 inhibition: cells incubated with 10% 
autologous serum 
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Figure 2.5: Tumor Necrosis Factor inhibition: whole blood 
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Figure 2.6: Interleukin-6 inhibition: whole blood 
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Table 2.1: Sample Identification: with and without 
10% autologous serum  
 
Sample ID Treatment S. typhimurium LPS 
C none 0 
VC Vehicle 
(10 µL DMSO) 
0 
P PMB (10 µM) 0 
EC EVK063 (10 µM) 0 
L none 100ng/mL 
PL PMB 10 µM 100ng/mL 
E10 EVK063 10 µM 100ng/mL 
E1 EVK063 1 µM 100ng/mL 
E0.1 EVK063 0.1 µM 100ng/mL 
E0.01 EVK063 0.01 µM 100ng/mL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample ID Treatment S. typhimurium LPS 
C None 0 
L None 2ng/mL 
P PMB 10µM 0 
PL PMB 10µM 2ng/mL 
EC EVK063 10µM 0 
E10 EVK063 10µM 2ng/mL 
Left
Righ
Hyb
Table 2.2: Sample identification: whole blood model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2.3: IL6 specific primers; product length: 214bp
 primer CCCCTGACCCAACTGCAA 
t primer TGTGCCCAGTGGACAGGTTT 
 Oligo CCTGCTGGCTAAGCTGCATTCACAG 
40 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2.4: Tumor Necrosis Factor and Interleukin 6
inhibition:  cells incubated without serumSample ID Tumor Necrosis 
Factor  
% inhibition 
Interleukin 6 
% inhibition 
C 100 100 
VC 98 96 
P 97 93 
EC 95 91 
L 0*+ 0*+
PL 96 90 
E10 95 88 
E1 21*+ 20*+
E0.1 30*+ 7*+
E0.01 6*+ 4*+
*comparison to PL with significance at p≤0.05 
+comparison to E10 with significance at p≤0.05  Table 2.5: Tumor Necrosis Factor and Interleukin 6 
inhibition:  cells incubated with 10% autologous serumSample ID Tumor Necrosis 
Factor  
% inhibition 
Interleukin 6 
% inhibition 
C 100 100 
VC 99 95 
P 98 95 
EC 95 92 
L 0*+ 0*+
PL 97 90 
E10 95 81 
E1 9*+ 5*+
E0.1 17*+ 5*+
E0.01 7*+ 2*+
*comparison to PL with significance at p≤0.05 
+comparison to E10 with significance at p≤0.05  
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Chapter 3 
Future Investigations 
While positive findings were obtained regarding the ability of EVK063 to attenuate 
cytokine production from lipopolysaccharide (LPS) stimulated equine peripheral blood 
mononuclear cells (PBMC’s), there is an imminent need for the continued exploration 
into the efficacy of EVK063.  While Tumor necrosis factor-α (TNF) production and 
Interleukin-6 (IL6) expression were reduced when compared with non-treated LPS 
stimulated samples, their values were elevated compared to control samples.  Therefore, 
further evaluation to determine the concentration of EVK063 that maximally inhibits 
cytokine production without displaying toxic effects on the cells in vitro would be 
prudent.  Given the results from previous evaluations and this study, a whole blood model 
should be used for additional in vitro evaluations of EVK063. 
We administered LPS and the assigned treatment to the cells at time 0.  In previous 
investigations, EVK063 exhibited a time dependent relationship of protection from LPS 
stimulation in a murine model.1  When administered as little as one hour post LPS 
challenge, all mice in the cohorts died after 24 hours.1  While factors predisposing 
patients to endotoxemia are documented, most causes are not recognized prior to insult.  
In select cases, the source of endotoxin can be successfully removed.  However, many 
times this is not possible; therefore, investigations evaluating the protective effects of 
EVK063 administered both pre and post LPS challenge are essential.  This investigation 
focused on the cytokines TNF and IL6.  Additional cytokines such as IL1, IL2 and IL6 
should be evaluated to determine if EVK063 has the ability to attenuate their production. 
 
 
47 
An NFkB induction assay has been utilized in lab animal models.2-4 and could provide 
valuable information if configured to evaluate equine samples.  If EVK063 could inhibit 
activation of the NFkB pathway, several devastating clinical signs could be reduced.  A 
p38 mitogen-activated kinase (MAPK) flow cytometric assay has also been utilized in lab 
animal models.2-4  However, it was unclear if p38 MAPK existed in equine cells as it had 
not been described in the literature.5  Recently, two separate studies have documented 
that p38 MAPK is essential in the equine LPS induction pathway.6,7  Therefore, 
adaptation of the p38 MAPK flow cytometric assay to equine cells would prove 
beneficial.   
Due to the severity of endotoxemia and the lack of appropriate therapies, multiple 
therapeutic agents are often used in conjunction.  Therefore, after establishing the 
appropriate concentration of EVK063 for maximal inhibition, investigations should 
evaluate possible synergy with additional therapeutics.  Non-steroidal anti-inflammatory 
drugs such as flunixin meglumine5,8-11, antibiotics5,8,9 and polymyxin B5,8,9,12-16 are 
therapeutic agents that are commonly used in endotoxic patients.  In vitro assessment 
using combinations of these agents with EVK063 should be considered. 
Once sufficient in vitro data are obtained demonstrating the ability of EVK063 to 
attenuate cytokine production, ex vivo investigations will follow.  Serial blood samples 
can be readily obtained after systemic administration of the compound.  These samples 
will be stimulated with LPS and evaluated as previously described in vitro.  Ex vivo 
studies will also allow evaluation of pharmacokinetic parameters and the efficacy of 
EVK063 following first pass effect.  The ex vivo investigations will also provide the 
proper dose and interval for in vivo assessment.  In vivo studies will provide the ultimate 
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test in the ability of EVK063 to not only inhibit cytokine production, but more 
importantly the manifestation of clinical signs.   
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